Company Savara Inc.

Stocks

SVRA

US8051111016

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 21:00:00 10/06/2026 BST			5-day change	1st Jan Change
5.090 ^USD	+3.25%		-3.05%	-15.59%

06-08	Savara Inc. Announces CFO Changes	CI
06-08	Savara Inc. Announces Step Down of Dave Lowrance as Chief Administrative Officer, Effective July 15, 2026	CI

Business description: Savara Inc.

Savara Inc. is a clinical-stage biopharmaceutical company. The Company is focused on rare respiratory diseases. The Companyâ€™s lead program, molgramostim inhalation solution (MOLBREEVI or molgramostim), is an inhaled biologic, specifically an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase III development for autoimmune pulmonary alveolar proteinosis (aPAP). MOLBREEVI is an inhaled formulation of recombinant human GM-CSF and is being developed for the treatment of aPAP. MOLBREEVI is administered once daily by inhalation via a high efficiency nebulizer, the eFlow Nebulizer System (PARI Pharma GmbH). Pulmonary alveolar proteinosis (PAP) is a rare lung disease characterized by the accumulation of surfactant in the alveoli (or air sacs) of the lungs. The Company is engaged in the advancement of the MOLBREEVI aPAP program and the Phase III IMPALA-2 clinical trial and outsourcing capital-intensive operations.

Number of employees: 70

Sales by Activity: Savara Inc.

Fiscal Period: December	2021 (USD)	2022 (USD)	2023 (USD)	2024 (USD)	2025 (USD)

See all business segments

Geographical breakdown of sales: Savara Inc.

Fiscal Period: December	2021 (USD)	2022 (USD)	2023 (USD)	2024 (USD)	2025 (USD)

See all geographic segments

Executive Committee: Savara Inc.

Manager	Title	Age	Since
Matthew Pauls CEO	Chief Executive Officer	55	30/11/2020
David Lowrance DFI	Director of Finance/CFO	58	31/10/2016
Yasmine Wasfi CTO	Chief Tech/Sci/R&D Officer	-	30/11/2023
Robert Lutz COO	Chief Operating Officer	57	12/02/2023
Temre Johnson IRC	Investor Relations Contact	-	31/10/2024

See SAVARA INC. governance

Composition of the Board of Directors: Savara Inc.

Director	Title	Age	Since
Nevan Elam BRD	Director/Board Member	58	31/01/2009
Richard Hawkins BRD	Director/Board Member	77	30/09/2010
Joseph McCracken BRD	Director/Board Member	72	30/09/2013
David Ramsay BRD	Director/Board Member	61	26/04/2017
Matthew Pauls CHM	Chairman	55	10/09/2020
An van Es-Johansson BRD	Director/Board Member	66	02/12/2019

Composition of the Board of Directors

Shareholders: Savara Inc.

Name	Stocks	%	Valuation
NEA Management Co. LLC 11.94 %	24,471,264	11.94 %	127 M $
Bain Capital Life Sciences LP 8.589 %	17,600,621	8.589 %	92 M $
Venrock Associates 6.705 %	13,740,375	6.705 %	71 M $
Deerfield Management Co. LP (Private Equity) 6.621 %	13,569,000	6.621 %	71 M $
TCG Crossover Management LLC 6.032 %	12,362,205	6.032 %	64 M $

List of SAVARA INC. shareholders

Company details: Savara Inc.

Savara, Inc.

One Summit Square

19047, Langhorne

+512 614 1848

http://www.savarapharma.com

Bio Therapeutic Drugs

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
SAVARA INC.	+3.25%	-3.05%	+118.45%	+65.26%	1.25B
ARGENX SE	+0.66%	+9.94%	+48.62%	+109.33%	54.5B
WUXI APPTEC CO., LTD.	+3.81%	-2.72%	+49.75%	+43.89%	41.73B
BIONTECH SE	-0.40%	-2.60%	-19.40%	-21.53%	21.87B
INSMED INCORPORATED	-7.23%	-11.53%	+1.04%	+371.18%	21.47B
WUXI BIOLOGICS (CAYMAN) INC.	-0.80%	-15.48%	+14.23%	-33.78%	15.79B
GENMAB A/S	-0.16%	+4.11%	+11.24%	-39.91%	15.29B
EXELIXIS, INC.	-0.77%	+1.90%	+23.66%	+175.43%	13.32B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	+3.61%	-0.55%	+16.69%	-	11.53B
SUMMIT THERAPEUTICS INC.	-8.68%	-13.40%	-40.90%	+633.15%	11.09B
Average	-0.68%	-1.33%	+22.34%	+144.78%	20.78B
Weighted average by Cap.	-0.22%	+1.01%	+23.68%	+120.13%